Fig. 1
A summary of various MCL-targeting agents, including BTKi and other small molecular inhibitors, antibody–drug conjugates, chimeric antigen receptor T cells, bispecific antibodies, and other immune modulators
Fig. 1 | Journal of Hematology & Oncology